In May 2017, in USA the company “Longeveron”, specializing on regenerative medicine drugs announced about the beginning of phase 1 of the clinical trial on the evaluation of the safety, tolerability and efficacy of mesenchymal stem cells in the treatment of Alzheimer’s disease.
Read more
Facebook